- /
- Supported exchanges
- / US
- / GALT.NASDAQ
Galectin Therapeutics Inc (GALT NASDAQ) stock market data APIs
Galectin Therapeutics Inc Financial Data Overview
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Galectin Therapeutics Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Galectin Therapeutics Inc data using free add-ons & libraries
Get Galectin Therapeutics Inc Fundamental Data
Galectin Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Galectin Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-08-14
- EPS/Forecast: -0.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Galectin Therapeutics Inc News
New
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock Transaction eliminates approximately $105.8 million in debt and increases market capitali...
Top Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focus
(RTTNews) - Today's top biotech gainers include Q32 Bio, following positive Phase 2 results for its hair loss treatment; Agenus, as it advances development of its colon cancer drug combination, botens...
Top Biotech Gainers: PLSM Inks Virtual Maternity Care Deal, ICCM Turns Heads, SLN Hits New High
(RTTNews) - Today's top gainers include Pulsenmore, which has entered into a collaboration with Ouma Health, a provider of virtual maternity care solutions in the United States; IceCure Medical, whose...
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH
Galectin Therapeutics GALT shares surged 11.4% on Tuesday after the company announced it had reached alignment with the FDA on key elements of the late-stage development program for belapectin, a gale...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.